X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DR. REDDYS LAB - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DR. REDDYS LAB NOVARTIS/
DR. REDDYS LAB
 
P/E (TTM) x 361.2 29.9 1,207.6% View Chart
P/BV x 17.8 2.9 606.6% View Chart
Dividend Yield % 1.6 0.9 176.1%  

Financials

 NOVARTIS   DR. REDDYS LAB
EQUITY SHARE DATA
    NOVARTIS
Mar-16
DR. REDDYS LAB
Mar-17
NOVARTIS/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs9823,397 28.9%   
Low Rs5562,560 21.7%   
Sales per share (Unadj.) Rs252.9856.5 29.5%  
Earnings per share (Unadj.) Rs62.178.0 79.7%  
Cash flow per share (Unadj.) Rs63.3139.9 45.2%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.30.7 193.6%  
Book value per share (Unadj.) Rs363.6739.8 49.1%  
Shares outstanding (eoy) m31.96165.74 19.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.03.5 87.5%   
Avg P/E ratio x12.438.2 32.4%  
P/CF ratio (eoy) x12.221.3 57.1%  
Price / Book Value ratio x2.14.0 52.5%  
Dividend payout %16.125.7 62.7%   
Avg Mkt Cap Rs m24,580493,632 5.0%   
No. of employees `0000.822.7 3.3%   
Total wages/salary Rs m1,80131,068 5.8%   
Avg. sales/employee Rs Th10,748.96,259.0 171.7%   
Avg. wages/employee Rs Th2,395.21,369.8 174.9%   
Avg. net profit/employee Rs Th2,641.1569.7 463.6%   
INCOME DATA
Net Sales Rs m8,083141,961 5.7%  
Other income Rs m8291,715 48.4%   
Total revenues Rs m8,913143,676 6.2%   
Gross profit Rs m23424,722 0.9%  
Depreciation Rs m3710,266 0.4%   
Interest Rs m2634 0.3%   
Profit before tax Rs m1,02515,537 6.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m17349 4.8%   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7522,965 25.4%   
Profit after tax Rs m1,98612,921 15.4%  
Gross profit margin %2.917.4 16.6%  
Effective tax rate %73.419.1 384.4%   
Net profit margin %24.69.1 270.0%  
BALANCE SHEET DATA
Current assets Rs m12,67896,837 13.1%   
Current liabilities Rs m2,43384,199 2.9%   
Net working cap to sales %126.78.9 1,423.7%  
Current ratio x5.21.2 453.1%  
Inventory Days Days3373 44.6%  
Debtors Days Days2298 23.0%  
Net fixed assets Rs m69102,552 0.1%   
Share capital Rs m160829 19.3%   
"Free" reserves Rs m11,460121,792 9.4%   
Net worth Rs m11,621122,621 9.5%   
Long term debt Rs m05,449 0.0%   
Total assets Rs m14,400218,165 6.6%  
Interest coverage x570.525.5 2,236.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.7 86.3%   
Return on assets %13.86.2 222.2%  
Return on equity %17.110.5 162.2%  
Return on capital %23.612.9 182.8%  
Exports to sales %0.754.6 1.4%   
Imports to sales %18.69.4 198.8%   
Exports (fob) Rs m6077,520 0.1%   
Imports (cif) Rs m1,50313,274 11.3%   
Fx inflow Rs m18681,670 0.2%   
Fx outflow Rs m1,82126,355 6.9%   
Net fx Rs m-1,63555,315 -3.0%   
CASH FLOW
From Operations Rs m2,53121,444 11.8%  
From Investments Rs m-8,270-18,404 44.9%  
From Financial Activity Rs m-386-3,692 10.4%  
Net Cashflow Rs m-6,125-1,144 535.4%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 5.4 37.0%  
FIIs % 1.6 35.3 4.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 21.5 15.3 140.5%  
Shareholders   41,647 75,885 54.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  MERCK LTD  GSK PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 23, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS